Similar articles

• Identification of type-specific anticancer histone deacetylase inhibitors: road to success.

  Noureen N, Rashid H, Kalsoom S. Noureen N, et al. Cancer Chemother Pharmacol. 2010 Sep;66(4):625-33. doi: 10.1007/s00280-010-1324-y. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2010. PMID: 20401613 Review.
• Histone deacetylase inhibitors in cancer therapy.

  Fouladi M. Fouladi M. Cancer Invest. 2006 Aug-Sep;24(5):521-7. doi: 10.1080/07357900600814979. Cancer Invest. 2006. PMID: 16939962 Review. No abstract available.
• HDAC Inhibitors--CHI's Third Annual Conference.

  Rosato RR. Rosato RR. IDrugs. 2010 Jan;13(1):13-5. IDrugs. 2010. PMID: 20024840
• Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

  Epping MT, Bernards R. Epping MT, et al. Int J Biochem Cell Biol. 2009 Jan;41(1):16-20. doi: 10.1016/j.biocel.2008.07.020. Epub 2008 Aug 12. Int J Biochem Cell Biol. 2009. PMID: 18765293 Review.
• Anticancer activities of histone deacetylase inhibitors.

  Bolden JE, Peart MJ, Johnstone RW. Bolden JE, et al. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133. Nat Rev Drug Discov. 2006. PMID: 16955068 Review.